Jack Y. Zhang - Mar 6, 2023 Form 4 Insider Report for Amphastar Pharmaceuticals, Inc. (AMPH)

Role
CEO & Chief Scientific Officer, Director, 10%+ Owner
Signature
/s/ Eva Wen, by power of attorney for Jack Y. Zhang
Stock symbol
AMPH
Transactions as of
Mar 6, 2023
Transactions value $
$0
Form type
4
Date filed
3/8/2023, 03:05 PM
Previous filing
May 23, 2022
Next filing
Mar 17, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMPH Common Stock Award $0 +81.4K +3.87% $0.00 2.19M Mar 6, 2023 Direct F1
transaction AMPH Common Stock Award $0 +34.3K +2.29% $0.00 1.53M Mar 6, 2023 See footnote F1, F2
holding AMPH Common Stock 6.83M Mar 6, 2023 See footnote F3
holding AMPH Common Stock 5K Mar 6, 2023 See footnote F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AMPH Employee Stock Option (right to buy) Award $0 +171K $0.00 171K Mar 6, 2023 Common Stock 171K $35.13 Direct F5
transaction AMPH Employee Stock Option (right to buy) Award $0 +72.3K $0.00 72.3K Mar 6, 2023 Common Stock 72.3K $35.13 See footnote F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported shares are represented by restricted stock units, or RSUs, which vest in four equal annual installments beginning on March 6, 2024.
F2 The securities are held of record by Mary Z. Luo. The reporting persons are husband and wife.
F3 The shares are held of record by Applied Physics & Chemistry Laboratories, Inc., of which the reporting persons and The Bill Luobei Zhang 2004 Irrevocable Trust are the sole owners.
F4 The shares are held of record in an account for the benefit of the reporting persons' son. The reporting persons disclaim beneficial ownership of these shares, and the inclusion of these shares in this report should not be deemed an admission of beneficial ownership of any such shares for purposes of Section 16, or for any other purpose.
F5 The shares subject to the option vest in four equal annual installments beginning on March 6, 2024.